Polymorphic cytochromes P450 in non-human primates.


Journal

Advances in pharmacology (San Diego, Calif.)
ISSN: 1557-8925
Titre abrégé: Adv Pharmacol
Pays: United States
ID NLM: 9015397

Informations de publication

Date de publication:
2022
Historique:
entrez: 11 8 2022
pubmed: 12 8 2022
medline: 16 8 2022
Statut: ppublish

Résumé

Cynomolgus macaques (Macaca fascicularis, an Old World monkey) are widely used in drug development because of their genetic and physiological similarities to humans, and this trend has continued with the use of common marmosets (Callithrix jacchus, a New World monkey). Information on the major drug-metabolizing cytochrome P450 (CYP, P450) enzymes of these primate species indicates that multiple forms of their P450 enzymes have generally similar substrate selectivities to those of human P450 enzymes; however, some differences in isoform, activity, and substrate specificity account for limited species differences in drug oxidative metabolism. This review provides information on the P450 enzymes of cynomolgus macaques and marmosets, including cDNA, tissue expression, substrate specificity, and genetic variants, along with age differences and induction. Typical examples of important P450s to be considered in drug metabolism studies include cynomolgus CYP2C19, which is expressed abundantly in liver and metabolizes numerous drugs. Moreover, genetic variants of cynomolgus CYP2C19 affect the individual pharmacokinetic data of drugs such as R-warfarin. These findings provide a foundation for understanding each P450 enzyme and the individual pharmacokinetic and toxicological results in cynomolgus macaques and marmosets as preclinical models. In addition, the effects of induction on some drug clearances mediated by P450 enzymes are also described. In summary, this review describes genetic and acquired individual differences in cynomolgus and marmoset P450 enzymes involved in drug oxidation that may be associated with pharmacological and/or toxicological effects.

Identifiants

pubmed: 35953160
pii: S1054-3589(22)00033-3
doi: 10.1016/bs.apha.2022.05.005
pii:
doi:

Substances chimiques

Cytochrome P-450 Enzyme System 9035-51-2
Cytochrome P-450 CYP2C19 EC 1.14.14.1

Types de publication

Journal Article Review Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

329-364

Informations de copyright

Copyright © 2022 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Conflicts of interest The authors declare that there are no conflicts of interest.

Auteurs

Yasuhiro Uno (Y)

Joint Faculty of Veterinary Medicine, Kagoshima University, Kagoshima, Japan. Electronic address: unoxx001@vet.kagoshima-u.ac.jp.

Shotaro Uehara (S)

Showa Pharmaceutical University, Machida, Tokyo, Japan.

Hiroshi Yamazaki (H)

Showa Pharmaceutical University, Machida, Tokyo, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH